Description
The RANK ligand inhibitor denosumab as novel therapeutic agent in the spectrum of cancer bone disease
Article: The RANK ligand inhibitor denosumab as novel therapeutic agent in the spectrum of cancer bone disease
€3.03
Related products
-
1 year subscription print edition of the Belgian Journal of Hematology (BJH)
€209.83 Add to cart -
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€3.03 Add to cart -
Article: Highlights in digestive oncology
€3.03 Add to cart -
Article: Highlights in respiratory oncology
€3.03 Add to cart
